Comparative Pharmacology
Head-to-head clinical analysis: DURYSTA versus YUVEZZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURYSTA versus YUVEZZI.
DURYSTA vs YUVEZZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prostaglandin analog; selective FP receptor agonist that increases uveoscleral outflow of aqueous humor.
YUVEZZI is not a recognized drug. No mechanism available.
One intracameral implant (10 mcg) administered in the study eye by a qualified ophthalmologist. A second administration may be performed if necessary, at least 3 months after the initial implant.
150 mg orally twice daily
None Documented
None Documented
Not applicable due to local ocular administration with minimal systemic exposure; bimatoprost systemic half-life is approximately 45 minutes after intravenous administration.
Terminal elimination half-life of 8–12 hours; permits twice-daily dosing in most indications
Minimal systemic absorption; no data on specific routes of elimination; expected to be primarily excreted via renal and biliary routes in small amounts.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog